IN8bio
IN8bio
INAB
NASDAQ
0.25
USD
0.00%
About
IN8bio, Inc. is a clinical-stage biopharmaceutical company. The Company is focused on the discovery, development and commercialization of gamma-delta T cell-based immunotherapies for cancer patients. Gamma-delta T cells are a specialized population of T cells that possess properties, including the ability to differentiate between healthy and diseased tissue.
The Company's lead program, INB-400, is in a Phase II clinical trial in which autologous, genetically modified gamma-delta T cells are assessed in glioblastoma (GBM). Its additional programs include Phase I trials in solid and hematologic tumors, including INB-200 for GBM and INB-100 for the treatment of patients with hematologic malignancies that are undergoing hematopoietic stem cell transplantation (HSCT).
In addition, the Company’s DeltEx platform has yielded a portfolio of preclinical programs, including INB-300 and INB-500, focused on addressing acute myeloid leukemia (AML) and other solid and hematological tumor types..
Financials Amount (in millions)
Income statement
Balance sheet
Cash flow
Ratios
| Price and Volume | |
|---|---|
| Volume | |
| Ten Day Average Volume | 194.7K |
| Three Month Average Volume | 8.3M |
| High Low | |
| Fifty-Two Week High | 2.48 USD |
| Fifty-Two Week Low | 0.5 USD |
| Fifty-Two Week High Date | 15 Dec 2023 |
| Fifty-Two Week Low Date | 29 Aug 2024 |
| Price and Volume | |
| Current Price | 0.5264 USD |
| Beta | -100,000 |
| Relative Price Change | |
| Four Week Relative Price Change | -36.93% |
| Thirteen Week Relative Price Change | -58.67% |
| Twenty-Six Week Relative Price Change | -56.08% |
| Fifty-Two Week Relative Price Change | -59.99% |
| Year-to-Date Relative Price Change | -67.79% |
| Price Change | |
| One Day Price Change | 1.39% |
| Thirteen Week Price Change | -55.76% |
| Twenty-Six Week Price Change | -51.71% |
| Five Day Price Change | -1.61% |
| Fifty-Two Week Price Change | -49.87% |
| Year-to-Date Price Change | -61.86% |
| Month-to-Date Price Change | -37.33% |
| Per Share Data | |
|---|---|
| Book Value | |
| Book Value Per Share (Last Fiscal Year) | 0.57608 USD |
| Book Value Per Share (Most Recent Quarter) | 0.29334 USD |
| Tangible Book Value Per Share (Last Fiscal Year) | 0.57608 USD |
| Tangible Book Value Per Share (Most Recent Quarter) | 0.29334 USD |
| EBITD | |
| EBITD Per Share (Trailing Twelve Months) | -0.78241 USD |
| Revenue | |
| Revenue Per Share (Last Fiscal Year) | 0 USD |
| Revenue Per Share (Trailing Twelve Months) | 0 USD |
| Dividend | |
| Dividend Per Share (Last Fiscal Year) | -99999.99 USD |
| Dividend Per Share (Trailing Twelve Months) | 0 USD |
| Dividend Per Share (5 Year) | -99999.99 USD |
| Earnings Per Share | |
| Excluding Extraordinary Items (Last Fiscal Year) | -1.00476 USD |
| Excluding Extraordinary Items (Trailing Twelve Months) | -0.83565 USD |
| Normalized (Last Fiscal Year) | -1.00476 USD |
| Basic Excluding Extraordinary Items (Last Fiscal Year) | -1.00476 USD |
| Basic Excluding Extraordinary Items (Trailing Twelve Months) | -0.83565 USD |
| Including Extraordinary Items (Last Fiscal Year) | -1.00476 USD |
| Including Extraordinary Items (Trailing Twelve Months) | -0.83565 USD |
| Cash | |
| Cash Per Share (Last Fiscal Year) | 0.49165 USD |
| Cash Per Share (Most Recent Quarter) | 0.22003 USD |
| Cash Flow Per Share (Last Fiscal Year) | -0.94211 USD |
| Cash Flow Per Share (Trailing Twelve Months) | -0.77871 USD |
| Free Cash Flow Per Share (Trailing Twelve Months) | -0.64365 USD |
| Margins | |
|---|---|
| Cash Flow Revenue | |
| Cash Flow Revenue (5 Year) | -100,000 |
| Cash Flow Revenue (Trailing Twelve Months) | -100,000 |
| Pretax Margin | |
| Pretax Margin (Trailing Twelve Months) | -99,999.99% |
| Pretax Margin (Last Fiscal Year) | -99,999.99% |
| Pretax Margin (5 Year) | -99,999.99% |
| Gross Margin | |
| Gross Margin (Last Fiscal Year) | -99,999.99% |
| Gross Margin (Trailing Twelve Months) | -99,999.99% |
| Gross Margin (5 Year) | -99,999.99% |
| Operating Margin | |
| Operating Margin (Last Fiscal Year) | -99,999.99% |
| Operating Margin (Trailing Twelve Months) | -99,999.99% |
| Operating Margin (5 Year) | -99,999.99% |
| Net Profit Margin | |
| Net Profit Margin (Last Fiscal Year) | -99,999.99% |
| Net Profit Margin (Trailing Twelve Months) | -99,999.99% |
| Net Profit Margin (5 Year) | -99,999.99% |
| Growth | |
|---|---|
| Book Value | |
| Book Value Per Share (5 Year) | 19.22% |
| Tangible Book Value (5 Year) | 39.94% |
| Free Operating Cash Flow | |
| Free Operating Cash Flow (5 Year) | -99,999.99% |
| Revenue | |
| Revenue Change MRQ vs 1 Year Ago | -99,999.99% |
| Revenue Growth (3 Year) | -99,999.99% |
| Revenue Change (Trailing Twelve Months) | -99,999.99% |
| Revenue Per Share Growth | -99,999.99% |
| Revenue Growth (5 Year) | -99,999.99% |
| Capital Spending Debt | |
| Capital Spending (5 Year) | -4.54% |
| Total Debt (5 Year) | -99,999.99% |
| Dividends | |
| Dividend Growth (3 Year) | -99,999.99% |
| Earnings Per Share | |
| EPS Change MRQ vs 1 Year Ago | 29.43% |
| EPS Change (Trailing Twelve Months) | 32.30% |
| EPS Growth (3 Year) | -99,999.99% |
| EPS Growth (5 Year) | -99,999.99% |
| EBITDA | |
| EBITDA (5 Year) | -99,999.99% |
| EBITDA (5 Year Interim) | -99,999.99% |
| Net Profit Margin | |
| Net Profit Margin Growth (5 Year) | -99,999.99% |
| Valuation | |
|---|---|
| Total Price to Book | |
| Price to Tangible Book (Last Fiscal Year) | 1 |
| Price to Tangible Book (Most Recent Quarter) | 2 |
| Price to Free Cash Flow | |
| Price to Free Cash Per Share (Last Fiscal Year) | -100,000 |
| Price to Free Cash Per Share (Trailing Twelve Months) | -100,000 |
| Net Debt | |
| Net Debt (Most Recent Quarter) | -8,796,000 |
| Net Debt (Last Fiscal Year) | -20,063,000 |
| Price to Sales | |
| Price to Sales (Last Fiscal Year) | -100,000 |
| Price to Sales (Trailing Twelve Months) | -100,000 |
| Price to Earnings | |
| PE Excluding Extraordinary Items (Last Fiscal Year) | -100,000 |
| PE Normalized (Last Fiscal Year) | -100,000 |
| PE Basic Excluding Extraordinary Items (Trailing Twelve Months) | -100,000 |
| PE Excluding Extraordinary Items High (Trailing Twelve Months) | -100,000 |
| PE Excluding Extraordinary Items Low (Trailing Twelve Months) | -100,000 |
| PE Including Extraordinary Items (Trailing Twelve Months) | -100,000 |
| Dividends | |
| Dividend Yield (5 Year) | -99,999.99% |
| Dividend Yield | -99,999.99% |
| Current Dividend Yield | 0.00% |
| Price to Book | |
| Price to Book (Last Fiscal Year) | 1 |
| Price to Book (Most Recent Quarter) | 2 |
| Financial Strength | |
|---|---|
| Debt to Equity | |
| Long Term Debt to Equity (Last Fiscal Year) | 2 |
| Long Term Debt to Equity (Most Recent Quarter) | 4 |
| Payout Ratio | |
| Payout Ratio (Last Fiscal Year) | -99,999.99% |
| Payout Ratio (Trailing Twelve Months) | -99,999.99% |
| Quick Ratio | |
| Quick Ratio (Last Fiscal Year) | -100,000 |
| Quick Ratio (Most Recent Quarter) | -100,000 |
| Enterprise Value | |
| Current Enterprise Value to Free Cash Flow (Last Fiscal Year) | -100,000 |
| Current Enterprise Value to Free Cash Flow (Trailing Twelve Months) | -100,000 |
| Current Ratio | |
| Current Ratio (Last Fiscal Year) | 5 |
| Current Ratio (Most Recent Quarter) | 3 |
| Free Cash Flow | |
| Free Cash Flow (Last Fiscal Year) | -23,940,000 |
| Free Cash Flow (Trailing Twelve Months) | -24,876,000 |
| Net Interest Coverage | |
| Net Interest Coverage (Last Fiscal Year) | -100,000 |
| Net Interest Coverage (Trailing Twelve Months) | -100,000 |
| Total Debt to Equity | |
| Total Debt to Equity (Last Fiscal Year) | 5 |
| Total Debt to Equity (Most Recent Quarter) | 10 |
| Management Effectiveness | |
|---|---|
| Return on Assets | |
| Return on Assets (Last Fiscal Year) | -89.91% |
| Return on Assets (Trailing Twelve Months) | -122.41% |
| Return on Assets (5 Year) | -74.18% |
| Return on Equity | |
| Return on Equity (Last Fiscal Year) | -125.90% |
| Return on Equity (Trailing Twelve Months) | -180.45% |
| Return on Equity (5 Year) | -196.82% |
| Return on Investment | |
| Return on Investment (Last Fiscal Year) | -108.07% |
| Return on Investment (Trailing Twelve Months) | -146.35% |
| Return on Investment (5 Year) | -84.42% |